PharmaShots | Incisive News in 3 Shots

Subscribe Now

Karuna Therapeutics

Karuna Therapeutics Reports the NDA Submission of KarXT to the US FDA for the Treatment of Schizophrenia

Karuna Therapeutics Reports the NDA Submission of KarXT to the US FDA for the Treatment of Schizophrenia

September 28, 2023

Karuna Therapeutics Entered into an Exclusive License Agreement with Goldfinch Bio for TRPC4/5 Product Candidates

Karuna Therapeutics Entered into an Exclusive License Agreement with Goldfinch Bio for TRPC4/5 Product Candidates

February 2, 2023

PharmaShots Weekly Snapshots (November 08, 12, 2021)

PharmaShots Weekly Snapshots (November 08, 12, 2021)

November 12, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us